# Molecular Phenotype Changes and Personalized Treatment for CRPC

> **NCT02208583** · NA · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Hormone Refractory Prostate Cancer

## Interventions

- **DRUG:** Docetaxel & Prednisone
- **DRUG:** DP & Targeted drugs
- **DRUG:** cisplatin & Etoposide
- **DRUG:** EP & Targeted drugs

## Key facts

- **NCT ID:** NCT02208583
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-06
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2014-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02208583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02208583, "Molecular Phenotype Changes and Personalized Treatment for CRPC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02208583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*